Focal boost SBRT in men with intermediate- and high-risk PCa: 5-year results of the hypo-FLAME trial

被引：0
|
作者：
Draulans, Cedric [1 ]
Haustermans, Karin [1 ,2 ]
Pos, Floris J. [3 ]
van der Heide, Uulke A. [3 ]
De Cock, Lisa [1 ]
van Zyp, Jochem R. N. Van der Voort [4 ]
de Boer, Hans C. J. [4 ]
Smeenk, Robert Jan [5 ]
Kunze-Busch, Martina [5 ]
Monninkhof, Evelyn M. [6 ]
De Roover, Robin [2 ]
Isebaert, Sofie [2 ]
Kerkmeijer, Linda G. W. [4 ,5 ]
机构：
[1] Katholieke Univ Leuven, Dept Oncol, Leuven, Belgium
[2] Univ Hosp Leuven, Dept Radiat Oncol, Leuven, Belgium
[3] Netherlands Canc Inst, Dept Radiat Oncol, Amsterdam, Netherlands
[4] Univ Med Ctr Utrecht, Dept Radiat Oncol, Utrecht, Netherlands
[5] Radboud Univ Nijmegen Med Ctr, Dept Radiat Oncol, Nijmegen, Netherlands
[6] Univ Med Ctr Utrecht, Julius Ctr Hlth Sci & Primary Care, Utrecht, Netherlands
来源：
RADIOTHERAPY AND ONCOLOGY | 2024年 / 194卷
关键词：
Prostate cancer; SBRT; Focal boost;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3396
引用
收藏
页码：S2647 / S2649
页数：4
相关论文
共 50 条
  • [21] 5-year survival and toxicity results of SIB radiotherapy in (very) high-risk prostate cancer
    Masson, I.
    Guerin-Charbonnel, C.
    Azria, D.
    Pommier, P.
    Mesgouez-Nebout, N.
    Giraud, P.
    Peiffert, D.
    Chauvet, B.
    Dudouet, P.
    Salem, N.
    Noel, G.
    Khalifa, J.
    Latorzeff, I.
    Mahe, M. A.
    Supiot, S.
    RADIOTHERAPY AND ONCOLOGY, 2023, 182 : S1186 - S1187
  • [22] Prospective results for 5-year survival and toxicity of moderately hypofractionated radiotherapy with simultaneous integrated boost (SIB) in (very) high-risk prostate cancer
    Masson, Ingrid
    Larriviere, Laurene
    Mahe, Marc-Andre
    Azria, David
    Pommier, Pascal
    Mesgouez-Nebout, Nathalie
    Giraud, Philippe
    Peiffert, Didier
    Chauvet, Bruno
    Dudouet, Philippe
    Salem, Naji
    Noel, Georges
    Khalifa, Jonathan
    Latorzeff, Igor
    Guerin-Charbonnel, Catherine
    Supiot, Stephane
    CLINICAL AND TRANSLATIONAL RADIATION ONCOLOGY, 2024, 44
  • [23] Sentinel node mapping in high-intermediate and high-risk endometrial cancer: analysis of 5-year oncologic outcomes
    Bogani, Giorgio
    Di Donato, Violante
    Malzoni, Mario
    Vizza, Enrico
    Papadia, Andrea
    Casarin, Jvan
    Ditto, Antonino
    Multinu, Francesco
    Fanfani, Francesco
    Ghezzi, Fabio
    Berretta, Roberto
    Tozzi, Roberto
    Vizzielli, Giuseppe
    Scambia, Giovanni
    Giannini, Andrea
    Raspagliesi, Francesco
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2024, 34 (SUPPL_1) : A152 - A152
  • [24] Sentinel node mapping in high-intermediate and high-risk endometrial cancer: Analysis of 5-year oncologic outcomes
    Cuccu, Ilaria
    Raspagliesi, Francesco
    Malzoni, Mario
    Vizza, Enrico
    Papadia, Andrea
    Di Donato, Violante
    Giannini, Andrea
    De Iaco, Pierandrea
    Perrone, Anna Myriam
    Plotti, Francesco
    Angioli, Roberto
    Casarin, Jvan
    Ghezzi, Fabio
    Cianci, Stefano
    Vizzielli, Giuseppe
    Restaino, Stefano
    Petrillo, Marco
    Sorbi, Flavia
    Multinu, Francesco
    Schivardi, Gabriella
    De Vitis, Luigi Antonio
    Falcone, Francesca
    Lalli, Luca
    Berretta, Roberto
    Mueller, Michael D.
    Tozzi, Roberto
    Chiantera, Vito
    Panici, Pierluigi Benedetti
    Fanfani, Francesco
    Scambia, Giovanni
    Bogani, Giorgio
    EJSO, 2024, 50 (04):
  • [25] Long term results of a prospective dose escalation phase-II trial: Interstitial pulsed-dose-rate brachytherapy as boost for intermediate- and high-risk prostate cancer
    Lettmaier, Sebastian
    Lotter, Michael
    Kreppner, Stephan
    Strnad, Annedore
    Fietkau, Rainer
    Strnad, Vratislav
    RADIOTHERAPY AND ONCOLOGY, 2012, 104 (02) : 181 - 186
  • [26] Short Androgen Suppression and Radiation Dose Escalation for Intermediate- and High-Risk Localized Prostate Cancer: Results of EORTC Trial 22991
    Bolla, Michel
    Maingon, Philippe
    Carrie, Christian
    Villa, Salvador
    Kitsios, Petros
    Poortmans, Philip M. P.
    Sundar, Santhanam
    van der Steen-Banasik, Elzbieta M.
    Armstrong, John
    Bosset, Jean-Francois
    Herrera, Fernanda G.
    Pieters, Bradley
    Slot, Annerie
    Bahl, Amit
    Ben-Yosef, Rahamim
    Boehmer, Dirk
    Scrase, Christopher
    Renard, Laurette
    Shash, Emad
    Coens, Corneel
    van den Bergh, Alphonsus C. M.
    Collette, Laurence
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15) : 1748 - +
  • [27] CONCOMITANT HYPOFRACTIONATED IMRT BOOST FOR LOCALIZED HIGH-RISK PROSTATE CANCER: FIVE YEAR RESULTS OF A PROSPECTIVE TRIAL
    Cheung, Patrick
    Morton, Gerard
    Szumacher, Ewa
    Danjoux, Cyril
    Chung, Hans
    Vesprini, Danny
    Chu, William
    Choo, Richard
    Deabreu, Andrea
    Zhang, Liying
    Loblaw, Andrew
    RADIOTHERAPY AND ONCOLOGY, 2016, 120 : S38 - S38
  • [28] A prospective trial of adjuvant therapy for high-risk uveal melanoma: assessing 5-year survival outcomes
    Binkley, Elaine
    Triozzi, Pierre L.
    Rybicki, Lisa
    Achberger, Susan
    Aldrich, Wayne
    Singh, Arun
    BRITISH JOURNAL OF OPHTHALMOLOGY, 2020, 104 (04) : 524 - 528
  • [29] High-risk behaviors associated with early smoking: Results from a 5-year follow-up
    Ellickson, PL
    Tucker, JS
    Klein, DJ
    JOURNAL OF ADOLESCENT HEALTH, 2001, 28 (06) : 465 - 473
  • [30] Ultra-hypofractionated radiation therapy for unfavourable intermediate-risk and high-risk prostate cancer is safe and effective: 5-year outcomes of a phase II trial
    Macias, Victor A.
    Barrera-Mellado, Inmaculada
    BJU INTERNATIONAL, 2020, 125 (02) : 215 - 225
12345